Finerenone

Therapeutic Group

Indication Dosage

Indication:
Finerenone is primarily indicated for adults with chronic kidney disease (CKD) associated with type 2 diabetes. It is used to:

Reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR).
Lower the chances of end-stage kidney disease (ESKD).
Decrease the risk of cardiovascular events such as non-fatal myocardial infarction and hospitalization for heart failure.

Dosage:

The initial recommended dose of Finerenone is 10 mg or 20 mg once daily, based on the patient’s kidney function (eGFR).
If the eGFR is ≥60 mL/min/1.73 m², start with 20 mg once daily.
If the eGFR is between 25-60 mL/min/1.73 m², start with 10 mg once daily.
The dose can be adjusted based on the patient’s potassium levels and kidney function during treatment.

Note: Regular monitoring of serum potassium levels and kidney function is essential to adjust the dose and ensure safe usage of the medication.

Content

10 mg Tablets
20 mg Tablets

Pregnancy

Not Recommended

Stability

mineralocorticoid receptor antagonist (MRA)

Contra Indications

Finerenone is contraindicated in patients with known hypersensitivity to the drug, severe hyperkalemia (potassium levels > 5.5 mEq/L), and severe renal impairment (eGFR < 25 mL/min/1.73 m²). It should also be avoided in individuals using other potassium-sparing medications or strong CYP3A4 inhibitors due to an increased risk of hyperkalemia.

Precautions

Finerenone is contraindicated in patients with known hypersensitivity to the drug, severe hyperkalemia (potassium levels > 5.5 mEq/L), and severe renal impairment (eGFR < 25 mL/min/1.73 m²). It should also be avoided in individuals using other potassium-sparing medications or strong CYP3A4 inhibitors due to an increased risk of hyperkalemia.

Lactation

Not Recommended

Side Effects

Hyperkalemia
Hypotension
Renal dysfunction
Gastrointestinal issues
Fatigue